At 45.4% CAGR, the Middle East & Africa Enzymatic DNA Synthesis Market is projected to be worth US$ 92.26 million by 2028, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa enzymatic DNA synthesis market was valued at US$ 9.76 million in 2022 and is expected to reach US$ 92.26 million by 2028, registering a CAGR of 45.4% from 2022 to 2028. Rising prevalence of genetic disorders and growing demand for enzymatic DNA synthesis procedure are the critical factors attributed to the Middle East & Africa enzymatic DNA synthesis market expansion.               

Down syndrome, autism spectrum disorder, cancer, diabetes, cystic fibrosis, and sickle cell anemia are a few of the commonly known genetic disorders. Per the Global Genes, more than 10,000 different genetic and rare diseases have been identified, and ~400 million people suffer from rare diseases. Some genetic disorders cause symptoms at birth, while others develop over time. The global burden of genetic diseases appears to be increasing. In conjunction with enzymatic assays, DNA synthesis shows greater diagnostic possibilities. This method provides important information about people at risk and helps them make important decisions regarding disease diagnosis and medication. Hence, with the rising prevalence of genetic disorders across the world, people are becoming more aware of the need for the early detection of these genetic flaws, which propels the growth of the Middle East & Africa enzymatic DNA synthesis market.

On the contrary, high costs and complex procedures hurdles the growth of Middle East & Africa enzymatic DNA synthesis market.

Based on product type, the Middle East & Africa enzymatic DNA synthesis market is bifurcated into custom DNA synthesis and DNA library synthesis. The DNA library synthesis segment held 53.2% share of Middle East & Africa enzymatic DNA synthesis market in 2022, amassing US$ 5.19 million. It is projected to garner US$ 47.70 million by 2028 to expand at 44.7% CAGR during 2022–2028.

Based on application, the Middle East & Africa enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and others. The synthetic biology segment held 50.2% share of Middle East & Africa enzymatic DNA synthesis market in 2022, amassing US$ 4.90 million. It is projected to garner US$ 45.63 million by 2028 to expand at 45.0% CAGR during 2022–2028.  

Based on end user, the Middle East & Africa enzymatic DNA synthesis market is segmented into academic & research institutes, biotech & pharmaceutical companies, diagnostic laboratories, and others. The biotech & pharmaceutical companies segment held 52.0% share of Middle East & Africa enzymatic DNA synthesis market in 2022, amassing US$ 5.07 million. It is projected to garner US$ 46.88 million by 2028 to expand at 44.9% CAGR during 2022–2028.

Based on country, the Middle East & Africa enzymatic DNA synthesis market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa.  Our regional analysis states that Saudi Arabia captured 34.0% share of Middle East & Africa enzymatic DNA synthesis market in 2022. It was assessed at US$ 3.31 million in 2022 and is likely to hit US$ 30.77 million by 2028, exhibiting a CAGR of 45.0% during the forecast period.  

Key players profiles in the Middle East & Africa enzymatic DNA synthesis market report DNA Script; GenScript Biotech Corporation; Synbio Technologies; Telesis Bio Inc; and Twist Bioscience, among others.

• Jan-2022, Telesis Bio, formerly Codex DNA, Inc. entered into a strategic collaboration and licensing agreement with Pfizer to access and further develop Codex DNA’s novel EDS technology for potential application by Pfizer for its mRNA-based vaccines and other biopharma products. Under this agreement, Pfizer gained early access to custom, state-of-the-art Company technology, including its proprietary short oligo ligation assembly (SOLA) EDS technology.
• Apr-2022, GenScript debut the highest throughput semiconductor chip for DNA synthesis in the industry at the annual built with biology global conference. Developed using GenScript's proprietary miniature semiconductor chip technology, the High-Density DNA Synthesis Chip allows the synthesis of 8.4 million unique oligos simultaneously, up to 170 bases per oligo. It is the first commercial platform for DNA digital data storage.                                     .

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com